Provided by Tiger Trade Technology Pte. Ltd.

Vanda Pharmaceuticals

8.57
+0.01000.12%
Volume:1.07M
Turnover:9.09M
Market Cap:506.46M
PE:-2.29
High:8.64
Open:8.59
Low:8.36
Close:8.56
52wk High:9.94
52wk Low:3.81
Shares:59.10M
Float Shares:49.48M
Volume Ratio:0.72
T/O Rate:2.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7413
EPS(LYR):-3.7413
ROE:-50.93%
ROA:-16.50%
PB:1.55
PE(LYR):-2.29

Loading ...

Vanda Pharmaceuticals Inc - Target Action Date of December 12, 2026

THOMSON REUTERS
·
Feb 25

Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

THOMSON REUTERS
·
Feb 25

Vanda Pharmaceuticals Director Honore Tage Disposes of Common Shares

Reuters
·
Feb 25

ImmunityBio Posts Upbeat Q4 Earnings, Joins Arcellx, Vanda Pharmaceuticals And Other Big Stocks Moving Higher On Monday

Benzinga
·
Feb 23

Unusually active option classes on open February 23rd

TIPRANKS
·
Feb 23

BUZZ-U.S. STOCKS ON THE MOVE-Merck, Alphabet, JPMorgan Chase

Reuters
·
Feb 23

BUZZ-U.S. STOCKS ON THE MOVE-Eli Lilly, Domino's, Novo Nordisk

Reuters
·
Feb 23

Top Premarket Gainers

MT Newswires Live
·
Feb 23

Vanda Pharmaceuticals Shares Jump 36% Premarket After US FDA Approves Co's Antipsychotic Pill

THOMSON REUTERS
·
Feb 23

Vanda Pharmaceuticals price target raised to $24 from $22 at H.C. Wainwright

TIPRANKS
·
Feb 23

Vanda Gets FDA Approval for Bysanti in Schizophrenia, Bipolar I Disorder; Shares Up Pre-Bell

MT Newswires Live
·
Feb 23

Why Vanda Pharmaceuticals Shares Are Trading Higher By Around 33%; Here Are 20 Stocks Moving Premarket

Benzinga
·
Feb 23

Vanda Pharmaceuticals announces FDA approval of Bysanti tablets

TIPRANKS
·
Feb 21

US FDA approves Vanda's psychiatric drug

Reuters
·
Feb 21

Vanda Pharmaceuticals Announces FDA Approval of Bysanti™ (Milsaperidone) for the Treatment of Bipolar I Disorder and Schizophrenia - a New Chemical Entity Opening New Horizons in Psychiatric Innovation

THOMSON REUTERS
·
Feb 21

Vanda Pharmaceuticals Inc - Bysanti Expected to Be Commercially Available in Q3 2026

THOMSON REUTERS
·
Feb 21

Vanda Pharmaceuticals Inc: Includes Warning for Bysanti, Increased Mortality in Elderly Patients With Dementia-Related Psychosis

THOMSON REUTERS
·
Feb 21

NASDAQ TRADE HALT HALT NEWS PENDING AT 04:17 PM

Reuters
·
Feb 21

Vanda Pharmaceuticals Sets 2026 Executive Salaries and Bonus Targets, Awards 2025 Bonuses and Equity Grants

Reuters
·
Feb 20

FDA Calendar: Vanda Stock (VNDA) Shows 126% Upside with Bysanti Decision on Deck

TIPRANKS
·
Feb 20